Unnamed: 0,title,date,stock,sentiment
509438.0,Shares of several healthcare companies are trading higher in sympathy with the overall market as optimism around a coronavirus vaccine increased following news from Moderna.,2020-05-18 10:23:00-04:00,FOLD,positive
509439.0,Amicus Therapeutics shares are trading lower after the company reported worse-than-expected Q1 EPS results.,2020-05-07 08:57:00-04:00,FOLD,neutral
509440.0,"The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500",2020-05-07 07:41:00-04:00,FOLD,negative
509441.0,"Amicus Therapeutics Q1 EPS $(0.350) Misses $(0.280) Estimate, Sales $60.500M Beat $57.490M Estimate",2020-05-07 07:30:00-04:00,FOLD,negative
509442.0,The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace,2020-05-03 08:45:00-04:00,FOLD,neutral
509443.0,Shares of several healthcare companies are trading higher amid optimistic coronavirus outlook following positive drug data from Gilead. This has raised hopes of a sooner return to spending and economic activity.,2020-04-17 10:04:00-04:00,FOLD,positive
509444.0,Shares of several healthcare companies are trading lower amid overall market weakness caused by the coronavirus which has decreased consumer spending and economic activity.,2020-04-15 10:05:00-04:00,FOLD,negative
509445.0,"Shares of several healthcare companies are trading lower, selling off from this week's strength. While the US stimulus package boosted economic optimism, demand concerns still exist amid the coronavirus outbreak.",2020-03-27 10:58:00-04:00,FOLD,positive
509446.0,Shares of several healthcare companies are trading lower in sympathy with the overall market on continued downward momentum caused by the coronavirus. The virus has had a negative impact on the global economy.,2020-03-16 09:40:00-04:00,FOLD,negative
509447.0,144 Biggest Movers From Friday,2020-03-16 05:03:00-04:00,FOLD,neutral
509448.0,Stocks That Hit 52-Week Lows On Thursday,2020-03-12 12:10:00-04:00,FOLD,negative
509449.0,Amicus Therapeutics Reaffurns FY2020 Sales Guidance of $250M-260M,2020-03-02 07:11:00-05:00,FOLD,neutral
509450.0,"Amicus Therapeutics Q4 EPS $(0.35) Misses $(0.27) Estimate, Sales $55.293M Beat $52.33M Estimate",2020-03-02 07:10:00-05:00,FOLD,negative
509451.0,"Earnings Scheduled For March 2, 2020",2020-03-02 04:08:00-05:00,FOLD,neutral
509452.0,"The Week Ahead In Biotech: COVID-19 Stocks In The Spotlight, Earnings Taper Off",2020-02-29 14:52:00-05:00,FOLD,neutral
509453.0,Shares of several healthcare and biotech companies are trading higher as unconfirmed reports of progress towards a coronavirus treatment raise investor sentiment amid the virus outbreak. NOTE: The WHO played down these reports and said there are no known treatments.,2020-02-05 09:47:00-05:00,FOLD,positive
509454.0,"Amicus Therapeutics shares are trading higher after Cantor Fitzgerald assumed coverage on the stock, maintaining an Overweight rating. The firm raised the price target from $19 to $20.",2020-02-04 10:26:00-05:00,FOLD,negative
509455.0,"Cantor Fitzgerald Assumes Amicus Therapeutics at Overweight, Raises $20 Price Target",2020-02-04 06:53:00-05:00,FOLD,negative
509456.0,146 Biotechnology Stocks Moving In Thursday's Session,2020-01-23 12:47:00-05:00,FOLD,neutral
509457.0,"Shares of healthcare and pharmaceutical companies are trading higher, not currently seeing any sector-specific news. NOTE: U.S. equities are trading higher ahead of today's signing of the U.S.-China phase one trade deal.",2020-01-15 11:57:00-05:00,FOLD,positive
509458.0,80 Biggest Movers From Yesterday,2020-01-15 04:48:00-05:00,FOLD,neutral
509459.0,Amicus Therapeutics shares are trading higher. Not seeing any news to justify the price action.,2020-01-14 11:29:00-05:00,FOLD,positive
509460.0,Amicus Therapeutics Sees Prelim. 2020 Galafold Revenue $250M-$260M; Sees FY19 Adj. Operating Expense $410M-$420M,2020-01-13 07:09:00-05:00,FOLD,neutral
509461.0,Amicus Therapeutics shares are trading higher after the company issued FY19 Galafold sales of $181 million.,2020-01-09 08:43:00-05:00,FOLD,positive
509462.0,Amicus Therapeutics Sees FY19 Galafold Sales $181M,2020-01-09 07:04:00-05:00,FOLD,neutral
509463.0,Amicus Therapeutics Gives Clinical Update On AT-GAA For Pompe Disease,2020-01-07 07:06:00-05:00,FOLD,neutral
509464.0,"Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus",2019-12-29 18:38:00-05:00,FOLD,neutral
509465.0,Amicus Therapeutics shares are trading lower. Not seeing any news to justify the price action.,2019-12-05 13:24:00-05:00,FOLD,neutral
509466.0,Amicus Therapeutics shares are trading higher. Not seeing any news to justify the price action.,2019-11-25 15:28:00-05:00,FOLD,positive
509467.0,"Janney On Amicus Therapeutics Also Notes 'Galafold revenue growth is encouraging', Natural history data supports superiority of AT-GAA over SOC ERT', 'Gene therapy development for Batten disease continues'",2019-11-11 14:11:00-05:00,FOLD,positive
509468.0,"Janney Reiterates Buy, $20 Target On Amicus Therapeutics Notes Co's 'Analyst Day Should Boost Investor Confidence'; Notes 'Financial discussions in the opening session a little unusual but not surprising'",2019-11-11 14:11:00-05:00,FOLD,negative
509469.0,Amicus Therapeutics shares are trading higher after the company reported better-than-expected Q3 EPS and sales results. The company also raised the lower end of its sales guidance from $160M to $170M.,2019-11-11 08:33:00-05:00,FOLD,neutral
509470.0,20 Stocks Moving in Monday's Pre-Market Session,2019-11-11 07:40:00-05:00,FOLD,neutral
509471.0,A Peek Into The Markets: US Stock Futures Signal Lower Start On Wall Street,2019-11-11 07:15:00-05:00,FOLD,negative
509472.0,Amicus Therapeutics Raises the Lower End of its Galafold Revenue Guidance from $160M to $170M,2019-11-11 07:07:00-05:00,FOLD,negative
509473.0,"Amicus Therapeutics Q3 EPS $(0.24) Beats $(0.32) Estimate, Sales $48.768M Beat $47.66M Estimate",2019-11-11 07:06:00-05:00,FOLD,neutral
509474.0,"Earnings Scheduled For November 11, 2019",2019-11-11 03:44:00-05:00,FOLD,neutral
509475.0,"The Week Ahead In Biotech: Adcom Test For Amarin's Fish Oil Pill, Agile Awaits FDA Verdict",2019-11-10 16:08:00-05:00,FOLD,positive
509476.0,Amicus Therapeutics shares are trading lower. Not seeing any news to justify the price action.,2019-10-30 12:56:00-04:00,FOLD,neutral
509477.0,Amicus Highlights Presentation Of Additional Interim Clinical Data For CLN6 Batten Disease Gene Therapy At 48th Annual Meeting Of The Child Neurology Society,2019-10-24 07:14:00-04:00,FOLD,neutral
509478.0,"Amicus Therapeutics Sees Prelim. Q3 Sales ~$48M vs $45.4M Estimate; Raises Lower End, Narrows FY19 Galafold Sales From $160M-$180M To $170M-$180M",2019-10-10 07:34:00-04:00,FOLD,negative
509479.0,45 Biggest Movers From Friday,2019-10-07 06:11:00-04:00,FOLD,neutral
509480.0,34 Stocks Moving In Friday's Mid-Day Session,2019-10-04 12:43:00-04:00,FOLD,neutral
509481.0,"Amicus Therapeutics shares are trading lower. NOTE: the stock saw increased volatility after the company announced ""positive"" data in Pompe Disease Phase 1/2 study of AT-GAA on October 2nd.",2019-10-04 10:43:00-04:00,FOLD,positive
509482.0,Amicus Therapeutics shares are trading higher in seemingly no company-specific news.,2019-10-03 13:10:00-04:00,FOLD,neutral
509483.0,Stocks That Hit 52-Week Lows On Wednesday,2019-10-02 10:55:00-04:00,FOLD,negative
509484.0,Amicus Therapeutics shares are trading lower after the company reported data from its Phase 1/2 clinical study of AT-GAA for Pompe disease.,2019-10-02 10:20:00-04:00,FOLD,neutral
509485.0,25 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2019-10-02 08:54:00-04:00,FOLD,neutral
509486.0,Stocks That Hit 52-Week Lows On Tuesday,2019-10-01 14:35:00-04:00,FOLD,negative
509487.0,"The Daily Biotech Pulse: Safety Scare For Anaptys' Psoriasis Drug, NewLink Genetics To Merge With Lumos, Insider Buy Props Up VBI Vaccines",2019-10-01 08:10:00-04:00,FOLD,negative
509488.0,"The Daily Biotech Pulse: ESMO Conference Gets Underway, J&J's Darzalex Snags Another Approval, Kaleido Biosciences CFO To Leave",2019-09-27 07:56:00-04:00,FOLD,positive
509489.0,"Shares of several healthcare companies are trading lower, potentially on recent Democratic primary polls showing Senator Elizabeth Warren in the lead.",2019-09-26 12:43:00-04:00,FOLD,neutral
509490.0,Amicus Therapeutics Option Alert: Jan 17 $13 Calls at the Ask: 1300 @ $0.201 vs 5155 OI; Earnings 11/4 Before Open [est] Ref=$8.65,2019-09-25 15:11:00-04:00,FOLD,positive
509491.0,Shares of many pharma/therapeutics stocks trading lower in sympathy with overall market weakness. Reports China is planning to cut prices for widely-used drugs may also be pressuring the sector today.,2019-09-24 14:01:00-04:00,FOLD,negative
509492.0,﻿Shares of several healthcare companies are trading higher with the overall market after the U.S. announced it is excluding and delaying the additional 10% tariff on certain products.,2019-08-13 11:53:00-04:00,FOLD,positive
509493.0,"Amicus Therapeutics Earlier Reported Q2 EPS $(0.36) Misses $(0.33) Estimate, Sales $44.13M Beat $41.13M Estimate",2019-08-08 10:26:00-04:00,FOLD,negative
509494.0,"The Daily Biotech Pulse: Glaukos To Buy Avedro, Mixed Adcom Vote For Gilead, Dynavax Offering",2019-08-08 07:11:00-04:00,FOLD,neutral
509495.0,Amicus Therapeutics shares trading lower despite news the company received marketing authorization for galafold for Fabry Disease in Argentina.,2019-08-02 12:38:00-04:00,FOLD,neutral
509496.0,Amicus Therapeutics Reports Received Marketing Authorization For Galafold For Fabry Disease In Argentina,2019-08-02 07:09:00-04:00,FOLD,neutral
509497.0,Amicus Therapeutics Reports Interim Clinical Data For AAV Gene Therapy In Children With CLN6 Batten Disease,2019-08-01 07:18:00-04:00,FOLD,neutral
509498.0,Shares of several drug manufacturing companies are trading lower. The Trump Administration earlier rolled back a proposal to eliminate rebates from government drug plans and commented on continued efforts to lower drug prices.,2019-07-11 10:36:00-04:00,FOLD,negative
509499.0,Amicus Therapeutics Option Alert: Jan 17 $13 Calls Sweep (34) near the Ask: 1000 @ $1.451 vs 36 OI; Earnings 8/6 Before Open [est] Ref=$11.64,2019-07-08 09:49:00-04:00,FOLD,positive
509500.0,Amicus Therapeutics And Catalent Biologics Enter Strategic Partnership For Gene Therapy Development And Manufacturing,2019-07-02 07:34:00-04:00,FOLD,neutral
509501.0,Amicus Therapeutics and Thermo Fisher's Brammer Bio Enter Strategic Gene Therapy Development and Manufacturing Collaboration,2019-07-01 07:08:00-04:00,FOLD,neutral
509502.0,Shares of several companies in the biotech space are trading higher after Pfizer announced it will acquire Array BioPharma.,2019-06-17 10:10:00-04:00,FOLD,positive
509503.0,"Amicus, United Rentals And More: 'Fast Money Halftime Report' Picks For June 4",2019-06-04 16:22:00-04:00,FOLD,positive
509504.0,Shares of several healthcare companies are trading higher with the overall US market. Recent comments out of China and Mexico has renewed trade optimism and lifted economic outlook.,2019-06-04 13:07:00-04:00,FOLD,positive
509505.0,Amicus Therapeutics Option Alert: Jun 21 $12 Calls Sweep (26) near the Ask: 578 @ $0.45 vs 2228 OI; Ref=$11.7975,2019-06-04 12:18:00-04:00,FOLD,positive
509506.0,"The Daily Biotech Pulse: Merrimack To Stay Independent, Chinese Cheer For Beigene, XBiotech Offering",2019-05-31 07:34:00-04:00,FOLD,positive
509507.0,56 Biggest Movers From Yesterday,2019-05-31 06:14:00-04:00,FOLD,neutral
509508.0,Amicus Therapeutics Prices Underwritten Offering of Common Stock,2019-05-31 04:34:00-04:00,FOLD,neutral
509509.0,44 Stocks Moving In Thursday's Mid-Day Session,2019-05-30 12:27:00-04:00,FOLD,neutral
509510.0,Amicus Therapeutics shares are trading lower after the company reported a $150 million common stock offering.,2019-05-30 09:15:00-04:00,FOLD,neutral
509511.0,"The Daily Biotech Pulse: Unity Biotech Licenses Anti-Aging Protein, Strong Results For Mereo's Brittle Bone Disease Drug",2019-05-30 07:33:00-04:00,FOLD,positive
509512.0,Amicus Therapeutics shares are trading lower after the company reported a $150 million common stock offering.,2019-05-29 16:21:00-04:00,FOLD,neutral
509513.0,Amicus Therapeutics Reports $150M Common Stock Offering,2019-05-29 16:15:00-04:00,FOLD,neutral
509514.0,Amicus Therapeutics And University Of Pennsylvania Announce Expansion Of Gene Therapy Collaboration,2019-05-29 06:34:00-04:00,FOLD,neutral
509515.0,"The Daily Biotech Pulse: Daiichi's Positive Breast Cancer Trial, Supernus Slumps, Axovant Reverse Split",2019-05-08 07:53:00-04:00,FOLD,negative
509516.0,Amicus Therapeutics Sees FY19 Galafold Sales $160M-$180M,2019-05-08 07:04:00-04:00,FOLD,neutral
509517.0,"Amicus Therapeutics Q1 EPS $(0.56) Down From $(0.28) YoY, Sales $34.05M Up From $16.696M YoY",2019-05-08 07:03:00-04:00,FOLD,neutral
509518.0,"The Daily Biotech Pulse: Earnings Deluge, G1 Therapeutics Positive FDA Meeting, Mustang Bio Offering",2019-04-30 08:06:00-04:00,FOLD,positive
509519.0,Amicus Therapeutics Highlights Presentation Of Preclinical Pompe Disease Gene Therapy Data At American Society Of Gene & Cell Therapy (ASGCT) 22nd Annual Meeting,2019-04-30 06:24:00-04:00,FOLD,neutral
509520.0,"Amicus Therapeutics S-3 Shows Registration For Mixed Securities Offering, No Size Disclosed",2019-04-24 17:31:00-04:00,FOLD,neutral
509521.0,"Shares of several healthcare stocks are trading higher in a potential rebound from last week's selloff. In an upgrade of HCA Healthcare, Raymond James analysts noted the selloff was 'based on legislation that has almost no chance of passing'",2019-04-23 11:52:00-04:00,FOLD,positive
509522.0,Amicus Therapeutics To Present Preclinical Pompe Disease Gene Therapy Data At The American Society Of Gene & Cell Therapy (ASGCT) 22nd Annual Meeting,2019-04-15 12:01:00-04:00,FOLD,neutral
509523.0,Janney: Amicus Therapeutics Has Significant Upside From Gene Therapy Pipeline,2019-04-05 12:27:00-04:00,FOLD,positive
509524.0,"Benzinga's Top Upgrades, Downgrades For April 5, 2019",2019-04-05 09:25:00-04:00,FOLD,positive
509525.0,Janney Capital Initiates Coverage On Amicus Therapeutics with Buy Rating,2019-04-05 07:01:00-04:00,FOLD,neutral
509526.0,Amicus Therapeutics Issued Two US Patents For Pompe Enzyme ATB200,2019-03-20 07:07:00-04:00,FOLD,neutral
509527.0,81 Biggest Movers From Friday,2019-03-04 05:39:00-05:00,FOLD,neutral
509528.0,64 Stocks Moving In Friday's Mid-Day Session,2019-03-01 13:18:00-05:00,FOLD,neutral
509529.0,"The Daily Biotech Pulse: Bristol-Myers Squibb-Celgene Deal Faces Setback, Syneos Hit By SEC Probe, FDA Cheer For T2 Biosystems",2019-02-28 08:24:00-05:00,FOLD,positive
509530.0,72 Biggest Movers From Yesterday,2019-02-26 05:31:00-05:00,FOLD,neutral
509531.0,42 Stocks Moving In Monday's Mid-Day Session,2019-02-25 12:25:00-05:00,FOLD,neutral
509532.0,Amicus Therapeutics shares are trading higher after the FDA granted breakthrough therapy designation to the company's AT-GAA.,2019-02-25 09:08:00-05:00,FOLD,positive
509533.0,"FDA Grants Breakthrough Therapy Designation (""BTD"") to Amicus' AT-GAA in Late Onset Pompe Disease",2019-02-25 04:03:00-05:00,FOLD,positive
509534.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs",2019-02-22 13:55:00-05:00,FOLD,neutral
509535.0,31 Stocks Moving In Thursday's Pre-Market Session,2019-02-21 08:09:00-05:00,FOLD,neutral
509536.0,WuXi Biologics  And Amicus Late Monday Reported Exclusive Manufacturing Partnership,2019-02-12 08:47:00-05:00,FOLD,positive
509537.0,"Amicus Therapeutics Highlights Data in Pompe Disease Phase 1/2 Study for Up to 24 Months Will Be Presented at 15th Annual WORLDSymposium Feb. 6, 2019",2019-02-05 16:38:00-05:00,FOLD,neutral
509538.0,"Benzinga's Top Upgrades, Downgrades For January 30, 2019",2019-01-30 09:17:00-05:00,FOLD,positive
509539.0,"Cantor Fitzgerald Initiates Coverage On Amicus Therapeutics with Overweight Rating, Announces $20 Price Target",2019-01-30 07:03:00-05:00,FOLD,negative
509540.0,"Benzinga's Top Upgrades, Downgrades For January 17, 2019",2019-01-17 09:23:00-05:00,FOLD,positive
509541.0,"The Daily Biotech Pulse: FDA Panel Backs Amgen's Hypertension Drug, Adamis Allergy Drug Launched In US",2019-01-17 08:06:00-05:00,FOLD,positive
509542.0,"A Peek Into The Markets: US Stock Futures Down, Morgan Stanley Earnings Miss In Focus",2019-01-17 06:56:00-05:00,FOLD,negative
509543.0,Citigroup Upgrades Amicus Therapeutics to Buy,2019-01-17 06:50:00-05:00,FOLD,neutral
509544.0,Amicus Therapeutics Sees FY2019 Sales $160.0M-180.0M vs $173.18M Est,2019-01-07 07:05:00-05:00,FOLD,neutral
509545.0,Amicus Therapeutics Reports Phase 1/2 Study Of CLN3 Batten Disease; Says 'Initial Safety is Encouraging with No Serious Adverse Events at 1 Month',2019-01-03 07:14:00-05:00,FOLD,positive
509546.0,"The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial",2018-12-21 07:58:00-05:00,FOLD,neutral
509547.0,"Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 20, 2018",2018-12-20 11:33:00-05:00,FOLD,negative
509548.0,"The Daily Biotech Pulse: Tilray Inks Cannabis Drink Pact, Double Delight For Merck, FDA Snub For Spectrum",2018-12-20 07:53:00-05:00,FOLD,positive
509549.0,Amicus Therapeutics Announces First Patient Dosed in Phase 3 PROPEL Pivotal Study of AT-GAA in Patients with Pompe Disease,2018-12-20 07:07:00-05:00,FOLD,neutral
509550.0,"Amicus Therapeutics Reports CFO Chip Baird To Leave Co., Daphne Quimi Named Replacement",2018-12-19 16:08:00-05:00,FOLD,negative
509551.0,"Guggenheim Initiates Coverage On Amicus Therapeutics with Buy Rating, Announces $18 Price Target",2018-12-18 07:09:00-05:00,FOLD,neutral
509552.0,"Stocks Which Set New 52-Week Low Yesterday, Tues., Nov. 20, 2018",2018-11-21 08:50:00-05:00,FOLD,negative
509553.0,"Stocks Which Set New 52-Week Low Yesterday, Wed., Nov. 14, 2018",2018-11-15 11:37:00-05:00,FOLD,negative
509554.0,"The Daily Biotech Pulse: Viking's Fatty Liver And Cholesterol Drug, Cyclacel Loss Narrows, Eton's Debut",2018-11-13 07:54:00-05:00,FOLD,negative
509555.0,Amicus Reaffirms FY18 Galafold Sales $80M-$90M,2018-11-05 07:01:00-05:00,FOLD,neutral
509556.0,"Amicus Therapeutics Q3 EPS $(0.84) Misses $(0.28) Estimate, Sales $20.596M Miss $23.57M Estimate",2018-11-05 07:01:00-05:00,FOLD,negative
509557.0,"The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-11-04 13:35:00-05:00,FOLD,neutral
509558.0,"Benzinga's Top Upgrades, Downgrades For October 29, 2018",2018-10-29 09:18:00-04:00,FOLD,positive
509559.0,"Citigroup Initiates Coverage On Amicus Therapeutics with Neutral Rating, Announces $12 Price Target",2018-10-29 07:28:00-04:00,FOLD,neutral
509560.0,"The Daily Biotech Pulse: AbbVie Takes Full Control Of Cystic Fibrosis Program, Amgen Slashes Cholesterol Drug Price",2018-10-25 08:03:00-04:00,FOLD,negative
509561.0,"Stocks Which Set New 52-Week Low Yesterday, October 23rd",2018-10-24 10:06:00-04:00,FOLD,negative
509562.0,"Stocks Which Set New 52-Week Low Yesterday, October 22nd",2018-10-23 09:54:00-04:00,FOLD,negative
509563.0,Amicus Therapeutics Enters Research and Development Collaboration with University of Pennsylvania to Develop AAV Gene Therapies,2018-10-08 07:05:00-04:00,FOLD,neutral
509564.0,Amicus Therapeutics To Highlight 18-Month Data In Pompe Disease Phase 1/2 Study At International Annual Congress of the World Muscle Society,2018-10-05 07:03:00-04:00,FOLD,positive
509565.0,Amicus Therapeutics shares are trading up 8.0% in the pre-market session after the company signed an agreement to acquire a gene therapy portfolio of ten clinical programs in neurologic lysosomal storage disorders.,2018-09-20 09:32:00-04:00,FOLD,positive
509566.0,UPDATE: Amicus Says Celenex Holders Will Also Be Eligible For Up To $75M In Tiered Sales Milestone Payments,2018-09-20 06:07:00-04:00,FOLD,neutral
509567.0,"UPDATE: Amicus Says Celenex Holders Will Be Eligible For Up To $15M In Development Milestones, $262M In BLA/MAA Submission, Approval Milestones, No Royalties Will Be Owed",2018-09-20 06:07:00-04:00,FOLD,positive
509568.0,"UPDATE: Amicus To Buy Portfolio Of 10 Clinical, Pre-Clinical Stage AAV Programs For $100M In Upfront Cash",2018-09-20 06:06:00-04:00,FOLD,neutral
509569.0,"Amicus Therapeutics Reports Purchase Of Global Development, Commercial Rights For 10 Gene Therapy Programs Developed At The Center for Gene Therapy at The Research Institute at Nationwide Children's Hospital and The Ohio State University",2018-09-20 06:05:00-04:00,FOLD,neutral
509570.0,"Amicus Therapeutics 10%+ Owner Joseph Edelman Buys 100,000 @ Avg Price: $11.74",2018-09-17 08:29:00-04:00,FOLD,neutral
509571.0,"Stocks Which Set New 52-Week Low Yesterday, September 13th",2018-09-14 09:30:00-04:00,FOLD,negative
509572.0,"The Daily Biotech Pulse: FDA Nod For STAAR, Supernus Opens Wallet, Principia Biopharma To Debut",2018-09-14 08:38:00-04:00,FOLD,neutral
509573.0,"Stocks Which Set New 52-Week Low Yesterday, September 12th",2018-09-13 10:19:00-04:00,FOLD,negative
509574.0,"Stocks Which Set New 52-Week Low Yesterday, September 11th",2018-09-12 15:29:00-04:00,FOLD,negative
509575.0,"Stocks Which Set New 52-Week Low Friday, September 7th",2018-09-10 16:38:00-04:00,FOLD,negative
509576.0,Amicus Therapeutics Announces Regulatory and Clinical Updates for AT-GAA in Pompe Disease,2018-09-10 07:02:00-04:00,FOLD,neutral
509577.0,"The Week Ahead In Biotech: Conferences, Clinical Trial Results, Earnings And IPOs",2018-09-09 16:46:00-04:00,FOLD,neutral
509578.0,"Stocks Which Set New 52-Week Low Yesterday, September 6th",2018-09-07 16:49:00-04:00,FOLD,negative
509579.0,"The Daily Biotech Pulse: Amgen-AstraZeneca, Boston Scientific Opens Wallet, Advaxis Offering",2018-09-07 07:55:00-04:00,FOLD,neutral
509580.0,"Benzinga's Top Upgrades, Downgrades For August 17, 2018",2018-08-17 08:59:00-04:00,FOLD,positive
509581.0,"Chardan Capital Downgrades Amicus Therapeutics to Neutral, Lowers Price Target to $15",2018-08-17 08:04:00-04:00,FOLD,negative
509582.0,"13F Filing From Omega Shows Dissolved Stakes In Amicus Therapeutics, Bristol-Myers, Cleveland Cliffs, Discovery Inc, and Array Biopharma",2018-08-14 11:19:00-04:00,FOLD,neutral
509583.0,"The Week Ahead: Nvidia, Retailer Earnings In Focus",2018-08-13 13:26:00-04:00,FOLD,neutral
509584.0,26 Stocks Moving In Monday's Pre-Market Session,2018-08-13 08:08:00-04:00,FOLD,neutral
509585.0,Amicus Therapeutics To Hold Conference Call Today To Discuss FDA Approval of Galafold,2018-08-13 06:59:00-04:00,FOLD,positive
509586.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs",2018-08-12 16:52:00-04:00,FOLD,neutral
509587.0,Amicus Therapeutics Announces FDA Approval for Migalastat (Galafold),2018-08-10 16:05:00-04:00,FOLD,positive
509588.0,REMINDER: Amicus Therapeutics has FDA PDUFA Date Monday the 13th for Migalastat,2018-08-10 13:05:00-04:00,FOLD,neutral
509589.0,Amicus Therapeutics Halted News Pending,2018-08-10 13:04:00-04:00,FOLD,neutral
509590.0,"The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmed's Antibiotic Faces FDA Panel",2018-08-07 08:23:00-04:00,FOLD,negative
509591.0,Amicus Raises Total Galafold Guidance From $75M-$85M To $80M-$90M,2018-08-07 07:09:00-04:00,FOLD,neutral
509592.0,"Amicus Therapeutics Q2 EPS $(0.33), Inline, Sales $21.3M Beat $19.16M Estimate",2018-08-07 07:09:00-04:00,FOLD,neutral
509593.0,Q2 Earnings Outlook For Amicus Therapeutics,2018-08-06 15:35:00-04:00,FOLD,neutral
509594.0,Attention Biotech Investors: Mark Your Calendar For These August PDUFA Dates,2018-08-01 07:38:00-04:00,FOLD,neutral
509595.0,"Benzinga's Daily Biotech Pulse: Pain Therapeutics Drops 70%, Neon To Begin Trading",2018-06-27 08:14:00-04:00,FOLD,negative
509596.0,5 Stocks Moving In Tuesday's After-Hours Session,2018-06-26 17:56:00-04:00,FOLD,neutral
509597.0,UPDATE: Amicus Says Will Begin Process Performance Qualification Runs At Commercial Scale Level For AT-GAA,2018-06-26 16:11:00-04:00,FOLD,neutral
509598.0,UPDATE: Amicus Says CHMP's SAWP Was Supportive Of Studying Added Patient Populations For AT-GAA,2018-06-26 16:10:00-04:00,FOLD,positive
509599.0,UPDATE: Amicus Says Pivotal Study Of AT-GAA In Pompe Disease Expected To Begin In 2H'18 'pending feedback from the Type C meeting with FDA which is on track for Q3'18',2018-06-26 16:10:00-04:00,FOLD,neutral
509600.0,"Amicus Therapeutics Reports Received Written Guidance From CHMP's Scientific Advice Working Party On AT-GAA Trial, Will Incorporate Feedback On Key Elements Of Nature, Design Of Study",2018-06-26 16:09:00-04:00,FOLD,positive
509601.0,Amicus Therapeutics Option Alert: Jul 20 $16 Calls at the Ask: 800 @ $1.4 vs 18648 OI; Earnings 8/6 Before Open [est] Ref=$16.77,2018-06-19 11:26:00-04:00,FOLD,positive
509602.0,Amicus Therapeutics Launches Galafold for Fabry Disease in Japan,2018-05-30 03:54:00-04:00,FOLD,neutral
509603.0,13F From Cooperman's Omega Shows Raised Stake In Amicus Theraputics,2018-05-15 10:16:00-04:00,FOLD,neutral
509604.0,"Benzinga's Daily Biotech Pulse: Valeant Earnings, Lipocine's FDA Watch, Invivo CFO Departure",2018-05-08 07:55:00-04:00,FOLD,neutral
509605.0,Amicus Therapeutics Sees Galafold Sales At High End Of $75M-$85M,2018-05-08 07:42:00-04:00,FOLD,neutral
509606.0,"Amicus Therapeutics Q1 EPS $(0.28) Beats $(0.36) Estimate, Sales $14.08M Miss $16.89M Estimate",2018-05-08 07:16:00-04:00,FOLD,negative
509607.0,@adamfeuerstein Tweet: $FOLD — Cautious language in the Q1 earnings press release re: regulatory filing for Pompe drug. Sounds like they have not yet convinced regulators to accept filing on current data...,2018-05-08 07:14:00-04:00,FOLD,positive
509608.0,Amicus Therapeutics Option Alert: May 18 $15 Calls Sweep (27) at the Ask: 757 @ $1.049 vs 1354 OI; Earnings 5/8 Before Open Ref=$14.71,2018-05-07 13:33:00-04:00,FOLD,positive
509609.0,"The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More",2018-05-06 18:19:00-04:00,FOLD,neutral
509610.0,Amicus Therapeutics Announces Approval of Galafold for Fabry Disease in Japan,2018-03-23 04:45:00-04:00,FOLD,positive
509611.0,The Most Attractively Priced Stocks In Leon Cooperman's Portfolio,2018-03-08 11:27:00-05:00,FOLD,positive
509612.0,Amicus Therapeutics 2018 Strategic Priority Is To Double Global Rev. For Galafold To $75-$85M,2018-02-28 07:06:00-05:00,FOLD,neutral
509613.0,"Amicus Therapeutics Reports FY17 EPS $(1.85) vs (1.77) Est., Sales $36.93M vs $36M Est.",2018-02-28 07:06:00-05:00,FOLD,neutral
509614.0,"The Week Ahead In Biotech: Earnings, PDUFA Dates And More",2018-02-25 15:50:00-05:00,FOLD,neutral
509615.0,Amicus Therapeutics Prices~19.35M Share Offering of Common Stock @$15.50/Share,2018-02-15 20:18:00-05:00,FOLD,positive
509616.0,Amicus Therapeutics Announces $250M Common Stock Offering,2018-02-14 16:32:00-05:00,FOLD,neutral
509617.0,13F From Cooperman's Omega Shows New 100K Share Stake In Amicus,2018-02-14 12:21:00-05:00,FOLD,positive
509618.0,Amicus Therapeutics Announces the FDA Has Accepted its NDA for Priority Review for Migalastat,2018-02-12 07:31:00-05:00,FOLD,positive
509619.0,Amicus Therapeutics Announces 'Positive' Data in Pompe Disease Phase 1/2 Study,2018-02-07 16:05:00-05:00,FOLD,neutral
509620.0,Mid-Day Market Update: Dow Drops Over 100 Points; KapStone Paper Shares Spike Higher,2018-01-29 12:08:00-05:00,FOLD,positive
509621.0,Amicus Therapeutics Announces Canadian Drug Expert Committee Grants Positive Recommendation for Reimbursement of Galafold,2018-01-29 07:32:00-05:00,FOLD,positive
509622.0,Amicus Therapeutics Option Alert: Feb 16 $13 Puts at the Bid: 2500 @ $0.3 vs 19 OI; Earnings 2/28 Before Open [est] Ref=$15.7,2018-01-12 11:28:00-05:00,FOLD,positive
509623.0,"Amicus, Hasbro, Sears, And More: 'Fast Money Halftime Report' Final Picks",2018-01-10 15:41:00-05:00,FOLD,neutral
509624.0,Amicus Therapeutics Sees FY18 Sales $75-$85M vs $88M Est.,2018-01-08 07:33:00-05:00,FOLD,neutral
509625.0,"Jim Cramer Weighs In On PGT Innovations, Teck Resources And Amicus Therapeutics",2018-01-08 07:17:00-05:00,FOLD,neutral
509626.0,Amicus Therapeutics Reports Submission Of NDA For Migalastat For Treatment Of Fabry Disease,2017-12-14 07:30:00-05:00,FOLD,neutral
509627.0,Amicus Therapeutics Option Alert: Apr 20 $14 Puts Sweep (19) at the Ask: 743 @ $2.8 vs 7549 OI; Ref=$13.0,2017-11-20 13:03:00-05:00,FOLD,positive
509628.0,"Amicus Therapeutics Reports Q3 Adj. EPS $(0.41) vs $(0.31) Est., Sales $10.9M vs $9.5M Est.",2017-11-08 07:15:00-05:00,FOLD,neutral
509629.0,10 Stocks Moving In Monday's After-Hours Session,2017-10-16 17:03:00-04:00,FOLD,neutral
509630.0,Secondary Offering Lockup For Amicus Therapeutics Today,2017-10-11 09:35:00-04:00,FOLD,neutral
509631.0,Watch These 10 Huge Put Purchases In Friday Trade,2017-10-06 04:17:00-04:00,FOLD,positive
509632.0,Benzinga's Option Alert Recap From October 5,2017-10-05 16:28:00-04:00,FOLD,positive
509633.0,Amicus Option Alert: Apr 20 $16 Puts Sweep (24) at the Ask: 720 @ $2.851 vs 21 OI; Ref=$15.72,2017-10-05 14:03:00-04:00,FOLD,positive
509634.0,Watch These 8 Huge Put Purchases In Thursday Trade,2017-10-05 04:10:00-04:00,FOLD,positive
509635.0,Benzinga's Option Alert Recap From October 4,2017-10-04 16:22:00-04:00,FOLD,positive
509636.0,15 Biggest Mid-Day Gainers For Wednesday,2017-10-04 12:10:00-04:00,FOLD,neutral
509637.0,Amicus Therapeutics Option Alert: Nov 17 $14 Puts Sweep (20) at the Bid: 529 @ $0.651 vs 86 OI; Ref=$16.18,2017-10-04 10:10:00-04:00,FOLD,negative
509638.0,5 Biggest Price Target Changes For Wednesday,2017-10-04 10:02:00-04:00,FOLD,neutral
509639.0,There's Good Cause To Be Excited About Amicus Therapeutics Clinical Program,2017-10-04 09:59:00-04:00,FOLD,positive
509640.0,25 Stocks Moving In Wednesday's Pre-Market Session,2017-10-04 08:07:00-04:00,FOLD,neutral
509641.0,Amicus Therapeutics +8.2% Premarket @$16.10; Co Announced Additional Positive Data in Pompe Disease Phase 1/2 Study at World Muscle Society,2017-10-04 06:38:00-04:00,FOLD,positive
509642.0,Adam Feuerstein  Tweet: I saw the full data presentation being given at WMS and it looks very consistent. This is a real Pompe drug. $FOLD,2017-10-04 06:29:00-04:00,FOLD,neutral
509643.0,Amicus Therapeutics Announces Additional Positive Data in Pompe Disease Phase 1/2 Study at World Muscle Society,2017-10-04 06:04:00-04:00,FOLD,positive
509644.0,Watch These 10 Huge Put Purchases In Thursday Trade,2017-09-28 04:13:00-04:00,FOLD,positive
509645.0,Benzinga's Option Alert Recap From September 27,2017-09-27 16:13:00-04:00,FOLD,positive
509646.0,Amicus Therapeutics Option Alert: Apr 20 $23 Puts Sweep (24) at the Bid: 708 @ $8.801 vs 0 OI; Ref=$15.1,2017-09-27 13:53:00-04:00,FOLD,positive
509647.0,Amicus Therapeutics' ATB200/AT2221 Granted Orphan Drug Designation by the FDA,2017-09-21 07:30:00-04:00,FOLD,positive
509648.0,Amicus Therapeutics Reports FDA Granted Fast Track Designation For Co.'s Migalastat For Treatment Of Fabry Disease,2017-09-19 07:31:00-04:00,FOLD,positive
509649.0,Amicus Therapeutics Reports Approval For Galafold For Treatment Of Fabry Disease In Canada,2017-09-14 16:11:00-04:00,FOLD,positive
509650.0,25 Stocks Moving In Wednesday's Pre-Market Session,2017-09-13 08:04:00-04:00,FOLD,neutral
509651.0,Amicus Therapeutics Phase 3 Study for SD-101 in Epidermolysis Bullosa Did Not Meet Primary Endpoints,2017-09-13 06:05:00-04:00,FOLD,neutral
509652.0,Watch These 5 Huge Put Purchases In Tuesday Trade,2017-09-12 04:20:00-04:00,FOLD,positive
509653.0,Benzinga's Option Alert Recap From September 11,2017-09-11 16:59:00-04:00,FOLD,positive
509654.0,Amicus Therapeutics Option Alert: Fri $13 Puts at the Ask: 2000 @ $0.35 vs 1031 OI; Ref=$13.77,2017-09-11 14:22:00-04:00,FOLD,positive
509655.0,Amicus Shares Volatile Over Last Min. As Traders Circulate Notice Of Compliance From Health Canada Related To Co.'s GALAFOLD,2017-09-08 10:17:00-04:00,FOLD,positive
509656.0,Watch These 3 Huge Call Purchases In Wednesday Trade,2017-09-06 04:13:00-04:00,FOLD,positive
509657.0,Benzinga's Option Alert Recap From September 5,2017-09-05 16:21:00-04:00,FOLD,positive
509658.0,Amicus Therapeutics Option Alert: Oct 20 $16 Calls Sweep (5) at the Ask: 500 @ $1.0 vs 323 OI; Ref=$13.99,2017-09-05 11:46:00-04:00,FOLD,positive
509659.0,Watch These 7 Huge Call Purchases In Thursday Trade,2017-08-31 06:05:00-04:00,FOLD,positive
509660.0,Benzinga's Option Alert Recap From August 30,2017-08-30 16:13:00-04:00,FOLD,positive
509661.0,Amicus Therapeutics Option Alert: Oct 20 $15 Calls Sweep (24) at the Ask: 1281 @ $1.5 vs 364 OI; Ref=$14.05,2017-08-30 14:12:00-04:00,FOLD,positive
509662.0,Watch These 8 Huge Put Purchases In Tuesday Trade,2017-08-29 04:59:00-04:00,FOLD,positive
509663.0,Amicus Therapeutics Option Alert: Oct 20 $11 Puts Sweep (19) at the Bid: 500 @ $0.601 vs 133 OI; Ref=$13.62,2017-08-28 12:00:00-04:00,FOLD,positive
509664.0,Amicus Therapeutics Announces Approval For Galafold In Australia,2017-08-15 16:03:00-04:00,FOLD,positive
509665.0,"13F From Farallon Capital Shows New Stakes In Akebia Therapeutics, Amicus Therapeutics, Cabela's, Huntsman, Ignyta, Savara",2017-08-14 13:54:00-04:00,FOLD,neutral
509666.0,"Amicus Therapeutics Q2 EPS $(0.34) vs $(0.36) Est., Sales $7.2M vs $6.7M Est.",2017-08-07 07:08:00-04:00,FOLD,neutral
509667.0,4 Momentum Plays To Watch,2017-07-19 14:54:00-04:00,FOLD,positive
509668.0,Mid-Afternoon Market Update: Crude Oil Up 1%; DragonWave Shares Plunge,2017-07-13 14:36:00-04:00,FOLD,negative
509669.0,10 Biggest Mid-Day Losers For Thursday,2017-07-13 12:39:00-04:00,FOLD,negative
509670.0,Mid-Day Market Update: Yandex Jumps Following Announcement Of Deal With Uber; Amicus Therapeutics Shares Drop,2017-07-13 12:04:00-04:00,FOLD,positive
509671.0,Mid-Morning Market Update: Markets Edge Higher; Delta Air Lines Profit Misses Expectations,2017-07-13 10:15:00-04:00,FOLD,positive
509672.0,Amicus Therapeutics Shares Down 6.5% In Pre-Market Following $225M Public Offering Of Common Stock Announced Wednesday,2017-07-13 08:56:00-04:00,FOLD,positive
509673.0,22 Stocks Moving In Thursday's Pre-Market Session,2017-07-13 08:04:00-04:00,FOLD,neutral
509674.0,Amicus Therapeutics Announces $225M Public Offering Of Common Stock,2017-07-12 16:02:00-04:00,FOLD,neutral
509675.0,Watch These 7 Huge Call Purchases In Wednesday Trade,2017-07-12 04:26:00-04:00,FOLD,positive
509676.0,Benzinga's Option Alert Recap From July 11,2017-07-11 16:20:00-04:00,FOLD,positive
509677.0,Mid-Afternoon Market Update: Crude Oil Up 1.5%; VOXX International Shares Plummet,2017-07-11 14:30:00-04:00,FOLD,negative
509678.0,Cowen Analyst Responds Following Amicus' Positive Migalastat News,2017-07-11 14:08:00-04:00,FOLD,positive
509679.0,Amicus Therapeutics Up 25% Following FDA Decision To Allow New Application For Migalastat,2017-07-11 12:26:00-04:00,FOLD,positive
509680.0,12 Biggest Mid-Day Gainers For Tuesday,2017-07-11 12:24:00-04:00,FOLD,neutral
509681.0,"Cowen On Amicus Therapeutics' Migalastat: Planned Q4 NDA 'has a good chance of
success'",2017-07-11 12:04:00-04:00,FOLD,positive
509682.0,Mid-Day Market Update: Halcon Resources Jumps After Announcing Sale of Williston Basin Assets; Shiloh Industries Shares Slide,2017-07-11 12:00:00-04:00,FOLD,positive
509683.0,Amicus Therapeutics Option Alert: Aug 18 $14 Calls at the Bid: 4250 @ $0.5 vs 12 OI; Ref=$12.86,2017-07-11 10:55:00-04:00,FOLD,positive
509684.0,Mid-Morning Market Update: Markets Mostly Flat; PepsiCo Profit Tops Expectations,2017-07-11 10:10:00-04:00,FOLD,positive
509685.0,20 Stocks Moving In Tuesday's Pre-Market Session,2017-07-11 08:10:00-04:00,FOLD,neutral
509686.0,Amicus Therapeutics +31% Premarket @$14.20; U.S. FDA Confirms Amicus Therapeutics May Submit NDA for Migalastat for Fabry Disease,2017-07-11 07:14:00-04:00,FOLD,neutral
509687.0,Amicus Therapeutics Says Planning to Submit NDA for Migalastat in Q4,2017-07-11 06:01:00-04:00,FOLD,neutral
509688.0,Amicus Therapeutics Submits Japanese NDA for Migalastat,2017-06-28 07:32:00-04:00,FOLD,neutral
509689.0,Amicus Says Top-Line Phase 3 Data for SD-101 On Track for Q3'17,2017-05-31 07:33:00-04:00,FOLD,neutral
509690.0,Amicus Therapeutics Reports Received Rare Pediatric Disease Designation for SD-101 for Patients with Epidermolysis Bullosa,2017-05-31 07:32:00-04:00,FOLD,neutral
509691.0,"Amicus Therapeutics Receives Rare Pediatric Disease Designation for SD-101, Top-Line Phase 3 Data On Track To Report Q3 2017; Designation Covers Broad Treatment of Epidermolysis Bullosa",2017-05-31 07:31:00-04:00,FOLD,neutral
509692.0,Option Alert: Amicus Therapeutics Sep 10.0 Calls: 2500 @  ASK  $1.05: 5061 traded vs 5579 OI:  Earnings 8/9 Before Open (est)  $7.73 Ref,2017-05-30 10:28:00-04:00,FOLD,positive
509693.0,Amicus Therapeutics Releases Investor Presentation,2017-05-22 08:48:00-04:00,FOLD,neutral
509694.0,22 Stocks Moving In Monday's Pre-Market Session,2017-05-22 08:07:00-04:00,FOLD,neutral
509695.0,22 Stocks Moving In Friday's Pre-Market Session,2017-05-19 08:11:00-04:00,FOLD,neutral
509696.0,UPDATE: Amicus Says Top-Line Data for SD-101 for Epidermolysis Bullosa On Track for Q3'17,2017-05-19 07:31:00-04:00,FOLD,neutral
509697.0,Amicus Therapeutics Offers Planned Analysis of Primary Endpoints in Phase 3 Epidermolysis Bullosa Study,2017-05-19 07:30:00-04:00,FOLD,neutral
509698.0,Amicus Therapeutics Announces 'Positive' Data from Initial Patients in Pompe Phase 1/2 Study,2017-05-15 07:17:00-04:00,FOLD,neutral
509699.0,"Amicus Therapeutics Reports Q1 EPS $(0.39) vs $(0.35) Est., Sales $4.2M",2017-05-09 07:34:00-04:00,FOLD,neutral
509700.0,Amicus Therapeutics Reports Launch of Galafold for Treatment of Fabry Disease in France,2017-05-02 07:41:00-04:00,FOLD,neutral
509701.0,"13G from Morgan Stanley on Amicus Therapeutics Shows Increased Stake to 5%, or ~7.2M Shares; BZ NOTE: Stake Increased from 3.07M Shares During Q4'16",2017-03-13 17:06:00-04:00,FOLD,positive
509702.0,Benzinga's Option Alert Recap From March 8,2017-03-08 17:51:00-05:00,FOLD,positive
509703.0,Amicus Therapeutics Launces Galafold In Italy,2017-03-08 16:21:00-05:00,FOLD,neutral
509704.0,Option Alert: Amicus Therapeutics Jul 8.0 Calls: 2500 @  ASK  $1.05: 2542 traded vs 1096 OI:  Earnings 5/3 Before Open (est)  $7.32 Ref,2017-03-08 14:05:00-05:00,FOLD,positive
509705.0,Mid-Afternoon Market Update: Avinger Drops After Q4 Results; MeetMe Shares Spike Higher,2017-03-07 14:35:00-05:00,FOLD,positive
509706.0,Mid-Day Market Update: Nimble Storage Surges Following Acquisition News; IDT Shares Plunge,2017-03-07 12:08:00-05:00,FOLD,positive
509707.0,The Unlikely Story Of How Amicus Therapeutics Came To Be,2017-03-02 13:31:00-05:00,FOLD,neutral
509708.0,20 Biggest Mid-Day Gainers For Wednesday,2017-03-01 12:46:00-05:00,FOLD,neutral
509709.0,25 Stocks Moving In Wednesday's Pre-Market Session,2017-03-01 08:19:00-05:00,FOLD,neutral
509710.0,Amicus Says Current Cash Position Expected to Fund Ongoing Operations Into 2H'18,2017-03-01 07:27:00-05:00,FOLD,neutral
509711.0,"Amicus Sees FY17 Total Net Cash Spend Including Third-Part Milestone Payments, CapEx $200M-$225M",2017-03-01 07:27:00-05:00,FOLD,neutral
509712.0,"Amicus Reports FY16 EPS $(1.49) vs $(1.40) Est., Sales $4.958M vs $5.7M Est.",2017-03-01 07:26:00-05:00,FOLD,neutral
509713.0,Amicus Therapeutics CEO John Crowley and Daughter Megan Appear at Trump Address to Congress,2017-02-28 21:56:00-05:00,FOLD,neutral
509714.0,Amicus Therapeutics Launches Galafold for Treatment of Fabry Disease in the United Kingdom,2017-02-27 08:02:00-05:00,FOLD,positive
509715.0,"Amicus Therapeutics Presents Additional Positive Preliminary Phase 1/2 Data at WORLDSymposium 2017; Biomarkers of Muscle Damage (AST, ALT and CK) Demonstrate Improving Trends in Majority of Patients",2017-02-16 04:17:00-05:00,FOLD,positive
509716.0,7 Biggest Price Target Changes For Tuesday,2017-01-24 11:27:00-05:00,FOLD,neutral
509717.0,Amicus Therapeutics Upgraded To Outperform; Overhangs Are Removed With Catalysts Ahead,2017-01-24 10:25:00-05:00,FOLD,neutral
509718.0,"Benzinga's Top Upgrades, Downgrades For January 24, 2017",2017-01-24 09:23:00-05:00,FOLD,positive
509719.0,"Baird Upgrades Amicus Therapeutics to Outperform, Raises price target to $10.00",2017-01-24 06:03:00-05:00,FOLD,neutral
509720.0,Mid-Day Market Update: Clayton Williams Energy Surges On Acquisition News; Christopher & Banks Shares Slide,2017-01-17 12:17:00-05:00,FOLD,positive
509721.0,Amicus Therapeutics Sees FY17 Net Cash Spend Of $200-$225M With Cash Runway To 2nd Half of 2018,2017-01-09 07:12:00-05:00,FOLD,neutral
509722.0,"AMICUS THERAPEUTICS INC: PERCEPTIVE LIFE SCIENCES MASTER FUND LTD (10%+) Buys 94,750 @ Avg Price: $4.96 (Form4)",2017-01-04 14:28:00-05:00,FOLD,neutral
509723.0,"National Institute for Health and Care Excellence (NICE) Issues Final Positive Recommendation for Galafold, Commercial Launch Expected In Ireland and England In Early 2017",2017-01-04 07:34:00-05:00,FOLD,positive
509724.0,"AMICUS THERAPEUTICS INC: PERCEPTIVE LIFE SCIENCES MASTER FUND LTD (10%+) Buys 85,275 @ Avg Price: $4.81 (Form4)",2016-12-27 11:00:00-05:00,FOLD,neutral
509725.0,Watch These 7 Huge Call Purchases In Friday Trade,2016-12-16 03:12:00-05:00,FOLD,positive
509726.0,Option Alert: FOLD Dec16 5.0 Calls Sweep: 946 @  ASK  $0.094: 1030 traded vs 5 OI:  Earnings 2/24 Before Open (est)  $4.73 Ref,2016-12-15 15:37:00-05:00,FOLD,positive
509727.0,Mid-Afternoon Market Update: Southwest Bancorp Rises On Acquisition News; Ocean Rig UDW Shares Tumble,2016-12-15 14:22:00-05:00,FOLD,positive
509728.0,15 Biggest Mid-Day Losers For Thursday,2016-12-15 13:18:00-05:00,FOLD,negative
509729.0,Mid-Day Market Update: Pier 1 Imports Surges On Strong Results; PacBio Shares Slide,2016-12-15 12:07:00-05:00,FOLD,positive
509730.0,Amicus Trading Down 12% PreMarket After Announcing Private Placement of $225M Convertible Debt After Close Wednesday,2016-12-15 09:07:00-05:00,FOLD,negative
509731.0,18 Stocks Moving In Thursday's Pre-Market Session,2016-12-15 08:16:00-05:00,FOLD,neutral
509732.0,Amicus Therapeutics Announces Positive Preliminary Data from Phase 1/2 Study of Novel Treatment Paradigm for Pompe Disease,2016-12-08 07:06:00-05:00,FOLD,positive
509733.0,Mid-Afternoon Market Update: Crude Oil Down 3.5%; Thor Industries Shares Surge On Earnings Beat,2016-11-29 14:32:00-05:00,FOLD,negative
509734.0,Amicus Therapeutics: Here's The Good News,2016-11-29 13:12:00-05:00,FOLD,positive
509735.0,15 Biggest Mid-Day Losers For Tuesday,2016-11-29 12:53:00-05:00,FOLD,negative
509736.0,Mid-Day Market Update: U.S. Stocks Turn Higher; Nivalis Therapeutics Shares Tumble After Failed Drug Trial,2016-11-29 12:09:00-05:00,FOLD,negative
509737.0,What Are The Next Steps For Amicus Therapeutics' Migalastat?,2016-11-29 11:02:00-05:00,FOLD,neutral
509738.0,Technical Take: Amicus Therapeutics Lower Despite Approval For Migalastat,2016-11-29 10:46:00-05:00,FOLD,negative
509739.0,Mid-Morning Market Update: Markets Edge Lower; Tiffany Tops Q3 Expectations,2016-11-29 10:05:00-05:00,FOLD,positive
509740.0,7 Biggest Price Target Changes For Tuesday,2016-11-29 09:39:00-05:00,FOLD,neutral
509741.0,20 Stocks Moving In Tuesday's Pre-Market Session,2016-11-29 08:22:00-05:00,FOLD,neutral
509742.0,Adam Feuerstein Tweets: $FOLD - FDA wants more data before allowing migalastat to be filed. Significant delay until 2019.,2016-11-28 16:14:00-05:00,FOLD,negative
509743.0,UPDATE: Amicus Therapeutics Will Host Conference Call Today at 4:30 p.m. EDT to Discuss US Regulatory Pathway for Migalastat for Fabry Disease,2016-11-28 16:12:00-05:00,FOLD,neutral
509744.0,UPDATE: Amicus Says Intermediate Expanded Access Program Expected to Commence in '17,2016-11-28 16:12:00-05:00,FOLD,neutral
509745.0,Amicus Therapeutics Announces Regulatory Plan For Full Approval Pathway For Migalastat,2016-11-28 16:10:00-05:00,FOLD,positive
509746.0,16 Stocks Moving In Monday's Pre-Market Session,2016-11-28 08:24:00-05:00,FOLD,neutral
509747.0,Watch These 7 Huge Call Purchases In Tuesday Trade,2016-11-22 01:02:00-05:00,FOLD,positive
509748.0,Option Alert: FOLD Dec16 10.0 Calls Sweep: 896 @  ASK  $0.45: 1158 traded vs 158 OI:  Earnings 2/24 Before Open (est)  $8.92 Ref,2016-11-21 14:31:00-05:00,FOLD,positive
509749.0,"Amicus Therapeutics Reports Q3 EPS $(0.33) vs. Est. $(0.32), Rev. $2.1M vs. Est. $1.7M",2016-11-07 07:31:00-05:00,FOLD,neutral
509750.0,Amicus Therapeutics Shares Spiking Higher,2016-10-20 14:09:00-04:00,FOLD,positive
509751.0,Mid-Morning Market Update: Markets Open Lower; Janus Capital And Henderson Group Announce All-Stock Merger,2016-10-03 10:06:00-04:00,FOLD,negative
509752.0,"15 Stocks Which Rallied Four Days, Then Sold Off Yesterday",2016-09-23 08:51:00-04:00,FOLD,neutral
509753.0,Amicus Therapeutics Releases Investor Presentation,2016-09-14 06:11:00-04:00,FOLD,neutral
509754.0,Mid-Morning Market Update: Markets Open Higher; USG To Divest L&W Supply For $670M,2016-08-29 09:56:00-04:00,FOLD,neutral
509755.0,Amicus Sees FY16 Net Cash Spend Outlook $135M-$155M,2016-08-09 07:45:00-04:00,FOLD,neutral
509756.0,Amicus Therapeutics Reports Q2 EPS $(0.40) vs. Est. $(0.33),2016-08-09 07:37:00-04:00,FOLD,neutral
509757.0,Amicus Therapeutics to Submit Japanese New Drug Application for Migalastat for Fabry Disease in 1H17,2016-08-03 07:37:00-04:00,FOLD,neutral
509758.0,"Amicus Shares Plunge Into Negative Territory, Now Down ~4% After Opening ~2% Higher",2016-07-28 10:19:00-04:00,FOLD,negative
509759.0,Watch These 10 Huge Call Purchases In Wednesday Trade,2016-07-27 01:22:00-04:00,FOLD,positive
509760.0,Option Alert: FOLD Jan17 10.0 Calls: 1011 @  ASK  $0.85: 1520 traded vs 12k OI:  Earnings 8/3  $6.26 Ref,2016-07-26 14:08:00-04:00,FOLD,positive
509761.0,Shares of Amicus Therapeutics Spike ~$0.20 Higher Over Last Few mins; Traders Attributing to SeekingAlpha Article 'A Look At Amicus Therapeutics',2016-07-13 10:06:00-04:00,FOLD,positive
509762.0,Amicus Therapeutics Expands Biologics Pipeline with New Preclinical Program for Cyclin-Dependent Kinase-Like 5 Deficiency With Acquisition Of MiaMed For $1.8M Cash And $4.7M In Amicus Stock,2016-07-06 16:02:00-04:00,FOLD,positive
509763.0,"Leerink Trades up Off The Open To $6.21/Share On Price Target Rise From $17 To $19 At Leerink, Incrementally Encouraged By FDA Response To Regulatory Path To Galafold In U.S.",2016-06-14 09:36:00-04:00,FOLD,positive
509764.0,"Ellen Rosenberg Buys 15,000 Shares of Amicus Therapeutics @$7.67/Share -Form 4",2016-06-06 16:10:00-04:00,FOLD,positive
509765.0,Mid-Afternoon Market Update: U.S. Stocks Turn Positive; American Woodmark Shares Fall On Earnings Miss,2016-06-02 14:32:00-04:00,FOLD,positive
509766.0,Amicus Therapeutics Gets European Commission Approval For Galafold in Patients With Fabry Disease,2016-05-31 10:55:00-04:00,FOLD,positive
509767.0,Today's Top 10 Pre-Market Gainers,2016-05-31 09:28:00-04:00,FOLD,positive
509768.0,10 Stocks Moving In Tuesday's Pre-Market Session,2016-05-31 08:21:00-04:00,FOLD,neutral
509769.0,Amicus Therapeutics Building Rare Disease Treatment Strategy; Bank Of America Initiates At Buy,2016-05-18 10:31:00-04:00,FOLD,neutral
509770.0,"The Market In 5 Minutes: Condoms, Rose, Condoms!",2016-05-18 09:35:00-04:00,FOLD,neutral
509771.0,Benzinga's Top Initiations,2016-05-18 09:30:00-04:00,FOLD,positive
509772.0,"Bank of America Initiates Coverage on Amicus Therapeutics at Buy, Announces $10.00 PT",2016-05-18 07:10:00-04:00,FOLD,neutral
509773.0,Amicus Therapeutics Reports Q1 EPS $(0.35) vs. Est. $(0.34),2016-05-03 07:17:00-04:00,FOLD,neutral
509774.0,Baird Initiates Coverage on Amicus Therapeutics at Neutral,2016-04-14 06:37:00-04:00,FOLD,neutral
509775.0,Chardan Analyst: Amicus Therapeutics Could Be Bought For $22.50/Share,2016-04-12 09:44:00-04:00,FOLD,neutral
509776.0,10 Stocks Moving In Tuesday's Pre-Market Session,2016-04-12 08:30:00-04:00,FOLD,neutral
509777.0,Amicus Therapeutics Gains 3% On Favorable EU Medicines Recommendation,2016-04-01 14:37:00-04:00,FOLD,positive
509778.0,"Amicus Therapeutics Shares Resume Trade, Now Up 10%",2016-04-01 12:15:00-04:00,FOLD,positive
509779.0,Shares of Amicus to Resume Trade at 12:15 p.m. EDT,2016-04-01 11:49:00-04:00,FOLD,positive
509780.0,Amicus Release Confirms Positive CHMP Opinion for Migalastat in EU,2016-04-01 11:44:00-04:00,FOLD,positive
509781.0,Amicus Therapeutics Halted News Pending,2016-04-01 11:20:00-04:00,FOLD,neutral
509782.0,EU Medicines Agency Recommends Approval of FOLD Fabry Disease Treatment Migalastat,2016-04-01 11:19:00-04:00,FOLD,positive
509783.0,Amicus Therapeutics Shares Falling,2016-04-01 10:14:00-04:00,FOLD,positive
509784.0,"Goldman Sachs Initiates Coverage on Amicus Therapeutics at Neutral, Announces $10.00 PT",2016-03-30 06:52:00-04:00,FOLD,neutral
509785.0,"Amicus Therapeutics Announces Expanded Access Program for Migalastat, ANSM Grants Temp. Authorization For Use For Patient Sales",2016-03-22 07:31:00-04:00,FOLD,positive
509786.0,"Amicus Therapeutics Shares Spiking, Shares Are Up 4% At $8.03/Share",2016-03-18 13:50:00-04:00,FOLD,positive
509787.0,Adam Feuerstein @adamfeuerstein $FOLD French regulators approved an ATU (temporary use approval) for migalastat. Co. expects CHMP opinion at next meeting (Mar. 29-April 1),2016-03-18 13:47:00-04:00,FOLD,positive
509788.0,Amicus Therapeutics CEO To Speak At JP Morgan's 2016 Spring Biotech Conf. Tuesday At 1PM edt,2016-03-14 10:18:00-04:00,FOLD,positive
509789.0,"Shares Of Amicus Therapeutics Selloff To LOD, Stock Down ~7% Today",2016-03-08 11:44:00-05:00,FOLD,positive
509790.0,"Janney Upgrades Amicus, Says EU Approval 'Likely'",2016-03-08 09:09:00-05:00,FOLD,positive
509791.0,Benzinga's Top Upgrades,2016-03-08 08:52:00-05:00,FOLD,positive
509792.0,CORRECTION:  Janney Capital Upgrades Amicus Therapeutics to Buy,2016-03-08 08:02:00-05:00,FOLD,neutral
509794.0,Mid-Day Market Update: Stage Stores Drops On Earnings Miss; Tumi Holdings Shares Jump,2016-03-03 12:06:00-05:00,FOLD,positive
509795.0,Option Alert: FOLD Apr16 10.0 Calls Sweep: 500 @  ASK  $0.65: 1550 traded vs 2650 OI: $7.38 Ref,2016-03-02 09:57:00-05:00,FOLD,positive
509796.0,"Amicus Therapeutics Full Year EPS ($1.20), Revenue $0",2016-02-26 07:04:00-05:00,FOLD,neutral
509797.0,Mid-Day Market Update: Dow Surges Over 250 Points; Firstmerit Shares Rise On Acquisition News,2016-01-26 12:02:00-05:00,FOLD,positive
509798.0,Amicus Pharma Provides Upcoming Year Strategy Update,2016-01-11 07:35:00-05:00,FOLD,neutral
509799.0,"Amicus Therapeutics Begins Phase 1/2 Study of Novel ERT for Treatment of Pompe Disease, 1st Patient To Be Dosed Early 2016",2015-12-22 07:30:00-05:00,FOLD,positive
509800.0,"Mid-Afternoon Market Update: Oramed Jumps Following Announcement of up to $50M Licensing, Investment Deal in China; Supercom Shares Dip",2015-11-30 15:02:00-05:00,FOLD,positive
509801.0,Point72 Largest Position Closures,2015-11-16 17:05:00-05:00,FOLD,neutral
509802.0,Amicus Therapeutics Reports Q3 Loss of $0.32/Share vs Loss of $0.25/Share Est.; FY15 Outlook Reaffirmed,2015-11-03 16:28:00-05:00,FOLD,negative
509803.0,Amicus Therapeutics Shares Sell Off Below $9,2015-11-03 12:43:00-05:00,FOLD,positive
509804.0,"Leerink Chats With Biotech Management, Names 20 Stocks To Buy Now",2015-10-06 14:08:00-04:00,FOLD,neutral
509805.0,Morning Market Gainers,2015-10-05 09:47:00-04:00,FOLD,neutral
509806.0,"Amicus Therapeutics Crashed 54%, But Chardan Is Buying",2015-10-05 09:40:00-04:00,FOLD,neutral
509807.0,Amicus Therapeutics +14% Premarket; Leerink Lowering PT from $23 to $21 While Maintaining Outperform Rating,2015-10-05 08:25:00-04:00,FOLD,negative
509808.0,Benzinga's Top #PreMarket Gainers,2015-10-05 08:13:00-04:00,FOLD,positive
509809.0,"UPDATE: Chardan Believes Valuation on Amicus 'now discounts extremely pessimistic outcomes,' Including 'pricing",2015-10-05 07:39:00-04:00,FOLD,negative
509810.0,"Chardan Capital Upgrades Amicus Therapeutics to Buy, Lowers PT to $8.00",2015-10-05 01:56:00-04:00,FOLD,negative
509811.0,Morning Market Losers,2015-10-02 09:51:00-04:00,FOLD,negative
509812.0,Amicus Therapeutics -36% Premarket Following Regulatory Update,2015-10-02 09:08:00-04:00,FOLD,neutral
509813.0,Amicus Therapeutics Provides U.S. Regulatory Update for Migalastat Monotherapy,2015-10-02 09:01:00-04:00,FOLD,neutral
509814.0,Mid-Afternoon Market Update: Cracker Barrel Drops Following Q4 Results; Intra-Cellular Therapies Shares Jump,2015-09-16 14:41:00-04:00,FOLD,positive
509815.0,Mid-Day Market Update: Crude Oil Surges Over 5%; Paycom Software Shares Tumble,2015-09-16 13:05:00-04:00,FOLD,negative
509816.0,Chardan's Amusa Is Downgrading Amicus Therapeutics: Here's Why,2015-09-16 11:40:00-04:00,FOLD,neutral
509817.0,Mid-Morning Market Update: Markets Mixed; FedEx Earnings Miss Estimates,2015-09-16 10:25:00-04:00,FOLD,negative
509818.0,Benzinga's Top Downgrades,2015-09-16 09:59:00-04:00,FOLD,positive
509819.0,"UPDATE: Chardan Cuts Amicus, Notes 'With FOLD shares outperforming the NBI by 101% YTD, we see",2015-09-16 08:28:00-04:00,FOLD,neutral
509820.0,Chardan Capital Downgrades Amicus Therapeutics to Neutral,2015-09-16 04:36:00-04:00,FOLD,neutral
509821.0,Amicus Therapeutics Announces Plan to Submit NDA for Migalastat for Fabry Disease,2015-09-15 07:00:00-04:00,FOLD,neutral
509822.0,Amicus Therapeutics Announces Plan to Submit NDA for Migalastat for Fabry Disease,2015-09-15 07:00:00-04:00,FOLD,neutral
509823.0,Amicus Therapeutics Announces Plan to Submit NDA for Migalastat for Fabry Disease,2015-09-15 07:00:00-04:00,FOLD,neutral
509824.0,"Benzinga's M&A Chatter for Monday August 31, 2015",2015-08-31 20:10:00-04:00,FOLD,neutral
509825.0,Amicus Therapeutics To Acquire Rare Disease For $229M In Cash,2015-08-31 06:02:00-04:00,FOLD,neutral
509826.0,5 Biotechs Leerink Analysts Are Watching,2015-08-11 14:23:00-04:00,FOLD,neutral
509827.0,Amicus Therapeutics Reports Q2 EPS $(0.27) vs. Est. $(0.24),2015-08-05 16:48:00-04:00,FOLD,neutral
509828.0,Mid-Morning Market Update: Markets Gain; Finish Line Beats Q1 Views,2015-06-26 11:33:00-04:00,FOLD,positive
509829.0,Morning Market Gainers,2015-06-26 09:42:00-04:00,FOLD,neutral
509830.0,Amicus Therapeutics Reports Galafold Marketing Authorization Application Validated by European Medicines Agency,2015-06-25 16:02:00-04:00,FOLD,positive
509831.0,Keep An Eye On These 10 After-Hours Movers,2015-06-25 07:02:00-04:00,FOLD,neutral
509832.0,MKM Looked To The Options Market To Find Its Top 10 M&A Targets,2015-06-23 14:05:00-04:00,FOLD,positive
509833.0,"Pier 1, BioMarin, HomeAway & Oracle Lead Wednesday's After-Hours Movers",2015-06-17 17:39:00-04:00,FOLD,neutral
509834.0,Amicus Therapeutics Announces Closing of Underwritten Offering of Common Stock and Full Exercise of Over-Allotment Option,2015-06-17 16:07:00-04:00,FOLD,neutral
509835.0,Benzinga's Volume Movers,2015-06-12 10:33:00-04:00,FOLD,neutral
509836.0,Amicus Therapeutics Prices ~16.9M Share Offering@$13.25/Share,2015-06-11 20:28:00-04:00,FOLD,positive
509837.0,Option Alert: Amicus Jun $13 Call; 1512 Contract Trade at Ask @$0.35; Now $12.84,2015-06-11 13:37:00-04:00,FOLD,positive
509838.0,Amicus Therapeutics Reports Offering Of $150M Stock,2015-06-10 16:01:00-04:00,FOLD,neutral
509839.0,"US Stock Futures Surge Ahead Of ADP Report, Beige Book",2015-06-03 07:30:00-04:00,FOLD,neutral
509840.0,Amicus Therapeutics Submits Marketing Authorization Application (MAA) for Full Approval of Fabry Monotherapy Galafold(TM) (Migalastat) in European Union,2015-06-03 07:01:00-04:00,FOLD,positive
509841.0,"Chardan Capital Initiates Coverage on Amicus Therapeutics at Buy, Announces $14.00 PT",2015-05-29 08:10:00-04:00,FOLD,neutral
509842.0,Amicus Therapeutics Announces Accelerated Assesment By European Regulators,2015-05-26 07:02:00-04:00,FOLD,neutral
509843.0,Amicus Therapeutics Reports Q1 Loss of $0.25/Share vs Loss of $0.21/Share Est.,2015-05-05 16:24:00-04:00,FOLD,negative
509844.0,13D Filing Shows Amicus Therapeutics Holder New Enterprise No Longer Owns Over 5% Of Company,2015-03-24 15:48:00-04:00,FOLD,negative
509845.0,Benzinga's Volume Movers,2015-03-19 10:37:00-04:00,FOLD,neutral
509846.0,Morning Market Gainers,2015-03-19 10:02:00-04:00,FOLD,neutral
509847.0,Benzinga's Top #PreMarket Gainers,2015-03-19 08:13:00-04:00,FOLD,positive
509848.0,US Stock Futures Edge Lower Ahead Of Jobless Claims Report,2015-03-19 07:43:00-04:00,FOLD,negative
509849.0,"Amicus Therapeutics Shares Rise 12% Premarket on Announcement of Positive Global Regulatory Updates from EMA, FDA Meetings for Fabry Monotherapy",2015-03-19 06:55:00-04:00,FOLD,positive
509850.0,"Amicus Therapeutics Provides Positive Global Regulatory Updates from EMA, FDA Meetings for Fabry Monotherapy",2015-03-19 06:02:00-04:00,FOLD,positive
509851.0,Option Alert: Amicus Therapeutics Mar $9 Call; 1612 Contract Trade at Ask @$0.70; Now $9.28,2015-03-11 11:49:00-04:00,FOLD,positive
509852.0,S-3 from Amicus Therapeutics Shows Registration for $250M Mixed Securities Shelf Offering,2015-03-03 17:17:00-05:00,FOLD,positive
509853.0,Amicus Reports Q4 Loss of $0.24/Share vs Loss of $0.18/Share Est.,2015-03-03 16:04:00-05:00,FOLD,negative
509854.0,Option Alert: Amicus Therapeutics Mar $9 Call; 1612 Contract Trade at Ask @$0.50; Now $8.61,2015-03-03 10:18:00-05:00,FOLD,positive
509855.0,US Stock Futures Jump Ahead Of Wholesale Inventories Data,2015-02-10 07:37:00-05:00,FOLD,neutral
509856.0,Amicus Therapeutics Announces Additional Positive Phase 3 Fabry Data on Patient Reported Outcomes at WORLDSymposium(TM) 2015,2015-02-10 07:13:00-05:00,FOLD,positive
509857.0,Amicus Therapeutics CEO Crowley Says Want to Develop a Pill for Fabry Disease that Can be Taken Every Other Day,2015-01-21 18:22:00-05:00,FOLD,positive
509858.0,Jim Cramer Interviews Amicus Therapeutics CEO John F. Crowley on Mad Money,2015-01-21 18:20:00-05:00,FOLD,negative
509859.0,Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 2,2015-01-12 11:03:00-05:00,FOLD,neutral
509860.0,"UPDATE: Amicus Therapeutics Expecting FY15 Cash Spend in $73-$83M Range; Announces COO Bradley Campbell to be Promoted to Pres, COO",2015-01-12 07:35:00-05:00,FOLD,positive
509861.0,Amicus Therapeutcis Announces 2015 Outlook,2015-01-12 07:34:00-05:00,FOLD,neutral
509862.0,Morning Market Gainers,2015-01-08 09:45:00-05:00,FOLD,neutral
509863.0,"Pharmaceuticals, Therapeutics And A Retailer On The Move Thursday Morning",2015-01-08 09:00:00-05:00,FOLD,neutral
509864.0,Benzinga's Top #PreMarket Gainers,2015-01-08 08:12:00-05:00,FOLD,positive
509865.0,Amicus Therapeutics Shares Rise 7% Premarket Following Report of Additional Positive Data on Important Cardiac Endpoint,2015-01-08 07:36:00-05:00,FOLD,positive
509866.0,Amicus Therapeutics Reports 'Additional Positive Data on an Important Cardiac Endpoint',2015-01-08 07:33:00-05:00,FOLD,positive
509867.0,NPS Pharmaceuticals Spikes 19% Amid Shire Bid Report,2014-12-17 11:15:00-05:00,FOLD,neutral
509868.0,Ian Estepan@ianestepan Tweet:   $SHPG also says that they are reviewing other targets - most logical other target $FOLD,2014-12-17 11:01:00-05:00,FOLD,neutral
509869.0,UPDATE: Amicus Expecting to Submit MAA in Mid-2015,2014-12-11 07:32:00-05:00,FOLD,neutral
509870.0,Amicus Therapeutics Announces Will Submit EMA for Migalastat Monotherapy for Fabry Disease,2014-12-11 07:31:00-05:00,FOLD,neutral
509871.0,These 4 Biotech Stocks Have Been On Fire,2014-12-08 15:31:00-05:00,FOLD,negative
509872.0,Amicus Therapeutics Announces Underwriters Full Exercise Of Over-Allotment Option At $6.50/share,2014-11-24 16:02:00-05:00,FOLD,neutral
509873.0,"Perceptive Advisors Buys 2,100,000 Shares of Amicus Therapeutics @$6.50/Share -Form 4",2014-11-19 14:59:00-05:00,FOLD,positive
509874.0,Benzinga's Top #PreMarket Losers,2014-11-19 08:18:00-05:00,FOLD,negative
509875.0,Amicus Therapeutics Prices 13.85M Share Offering @$6.50/Share,2014-11-18 19:31:00-05:00,FOLD,positive
509876.0,"Mid-Day Losers From November 18: Omega Protein, Urban Outfitters, Celldex Therapeutics, Amicus Therapeutics, Inter Parfums",2014-11-18 12:58:00-05:00,FOLD,negative
509877.0,Amicus Therapeutics Announces $75M Stock Offering,2014-11-17 16:00:00-05:00,FOLD,neutral
509878.0,Mid-Afternoon Market Update: Tyson Rises After Q4 Results; DreamWorks Shares Decline,2014-11-17 14:51:00-05:00,FOLD,positive
509879.0,Mid-Day Market Update: Allergan Jumps On Actavis Bid; Denbury Resources Shares Slip,2014-11-17 13:23:00-05:00,FOLD,positive
509880.0,"Midday Gainers From November 17: Celldex Therapeutics, Amicus Therapeutics, Baker Hughes, Allergan",2014-11-17 12:34:00-05:00,FOLD,neutral
509881.0,Mid-Morning Market Update: Markets Edge Lower; Halliburton To Acquire Baker Hughes For $34.6 Billion,2014-11-17 10:42:00-05:00,FOLD,negative
509882.0,Morning Market Movers,2014-11-17 09:51:00-05:00,FOLD,neutral
509883.0,Benzinga's Top #PreMarket Gainers,2014-11-17 08:08:00-05:00,FOLD,positive
509884.0,Amicus Therapeutics Reports Positive Phase 3 Data on Cardiac and Composite Endpoints from Fabry Monotherapy Study 012 at ASN,2014-11-15 10:22:00-05:00,FOLD,positive
509885.0,"Amended 13G Filing from GlaxoSmithKline on Amicus Therapeutics Shows Liquidated Position; Had Shown 14.38% Stake as of Dec. 31st, 2013",2014-10-28 14:13:00-04:00,FOLD,neutral
509886.0,Amicus Therapeutics Reports Additional Positive Phase 3 Data from Fabry Monotherapy Study 011 ,2014-10-19 19:28:00-04:00,FOLD,positive
509887.0,Amicus Therapeutics Shares Spike Higher; Positive Note Being Passed Around Mentioning Possible Use of Drug for Parkinson's,2014-10-08 14:52:00-04:00,FOLD,positive
509888.0,Top 5 Biotech Stocks Over The Past Year,2014-10-06 14:28:00-04:00,FOLD,positive
509889.0,"3 Cheap Biotech Stocks Analysts Love: Ohr Pharmaceutical Inc, Merrimack & Amicus",2014-09-08 14:25:00-04:00,FOLD,positive
509890.0,Top 5 Performing Biotech Stocks Of 2014,2014-09-03 12:08:00-04:00,FOLD,positive
509891.0,Morning Market Movers,2014-08-29 09:41:00-04:00,FOLD,neutral
509892.0,The Biotech Stock With The Best One-Week Performance,2014-08-25 15:46:00-04:00,FOLD,positive
509893.0,Stocks Hitting 52-Week Highs,2014-08-20 10:15:00-04:00,FOLD,neutral
509894.0,Morning Market Movers ,2014-08-20 09:49:00-04:00,FOLD,neutral
509895.0,Benzinga's Top #PreMarket Gainers,2014-08-20 08:10:00-04:00,FOLD,positive
509896.0,Amicus Announces Migalastat Met Both Co-Primary Endpoints of Comparability to ERT on Both Key Measures of Kidney Function,2014-08-20 06:10:00-04:00,FOLD,neutral
509897.0,Amicus EPS -$0.22 vs -$0.23est,2014-08-07 16:26:00-04:00,FOLD,neutral
509898.0," Amicus Therapeutic Shareholder Perceptive Advisors Buys 4,000,000 Shares @$3.50/Share -Form 4",2014-07-01 11:00:00-04:00,FOLD,positive
509899.0,Morning Market Movers ,2014-07-01 09:35:00-04:00,FOLD,neutral
509900.0,Amicus Extending Rally On Upgrades,2014-07-01 09:25:00-04:00,FOLD,neutral
509901.0,Benzinga's Top Upgrades,2014-07-01 08:23:00-04:00,FOLD,positive
509902.0,"Leerink Partners Upgrades Amicus Therapeutics, Inc. to Outperform, Raises PT to $6.00",2014-07-01 08:19:00-04:00,FOLD,neutral
509903.0,"Janney Capital Upgrades Amicus Therapeutics, Inc. to Buy, Raises PT to $5.00",2014-07-01 08:18:00-04:00,FOLD,neutral
509904.0,"Amicus Therapeutics Shares Rise 13% Premarket, May be Attributed to Upgrades from Janney, Leerink",2014-07-01 08:10:00-04:00,FOLD,positive
509905.0,Benzinga's Top #PreMarket Gainers,2014-07-01 08:06:00-04:00,FOLD,positive
509906.0,"JP Morgan Upgrades Amicus Therapeutics, Inc. to Overweight",2014-06-30 12:37:00-04:00,FOLD,neutral
509907.0,"Fold Shares Move to New Highs, Following JPMorgan Upgrade",2014-06-30 11:58:00-04:00,FOLD,positive
509908.0,Amicus Therapeutics Reports Phase 3 Fabry Monotherapy Study 012 Top Line Data Expected in Q3,2014-06-30 07:17:00-04:00,FOLD,positive
509909.0,"Amicus Therapeutics Chairman Crowley Buys 25,000 Shares @$2.69/Share -Form 4",2014-06-17 17:18:00-04:00,FOLD,positive
509910.0,"Amicus Therapeutics, Inc. Reports Q1 EPS of $(0.25) vs $(0.24) Est",2014-05-05 16:08:00-04:00,FOLD,neutral
509911.0,Morning Market Movers ,2014-04-29 09:43:00-04:00,FOLD,neutral
509912.0,Benzinga's Top #PreMarket Gainers,2014-04-29 08:09:00-04:00,FOLD,positive
509913.0,"Adam Feuerstein tweets: '$FOLD Just remember Study 011 failed last year, FDA approved changes but also said it could no longer be used for approval.'",2014-04-29 07:37:00-04:00,FOLD,negative
509914.0,"Amicus Therapeutics, Inc. Reports Q4 EPS of $(0.22) vs $(0.32) Est",2014-03-03 16:01:00-05:00,FOLD,neutral
509915.0,"Earnings Scheduled For March 3, 2014",2014-03-03 04:42:00-05:00,FOLD,neutral
509916.0,An S-3 Filing from Amicus Shows Registration for 9.1M Shares for Resale,2013-12-16 13:45:00-05:00,FOLD,positive
509917.0,13G Filing from Redmile Group Shows 15.14% Stake in Amicus Therapeutics,2013-11-29 11:28:00-05:00,FOLD,neutral
509918.0,UPDATE: J.P. Morgan Downgrades Amicus Therapeutics On Cautious View of Migalastat Monotherapy,2013-11-21 07:27:00-05:00,FOLD,negative
509919.0,"JP Morgan Downgrades Amicus Therapeutics, Inc. to Neutral",2013-11-21 06:24:00-05:00,FOLD,positive
509920.0,"Shares of QLT, Amicus, LifeVantage to Resume Trading at 4:30PM EST",2013-11-20 16:14:00-05:00,FOLD,positive
509921.0,"Amicus Therapeutics, Glaxo Revise Fabry Deal, GSK Will Receive No Upfront Payment from Amicus, Glaxo Will Further Invest $3M in Amicus",2013-11-20 16:02:00-05:00,FOLD,negative
509922.0,Gilead Sciences Leads In Rising Short Interest Among Biotechs ,2013-11-12 16:41:00-05:00,FOLD,positive
509923.0,"Amicus Therapeutics, Inc. Reports Q3 EPS of $(0.29) vs $(0.34) Est",2013-11-12 08:13:00-05:00,FOLD,neutral
509924.0,"Short Sellers Retreat From Biogen Idec, Move On Pharmacyclics (BIIB, BMRN, PCYC)",2013-10-25 15:36:00-04:00,FOLD,positive
509925.0,"Leerink Swann Downgrades Amicus Therapeutics, Inc. to Market Perform",2013-10-24 09:37:00-04:00,FOLD,neutral
509926.0,"BioMarin, Celgene Lead Trend in Biotech Short Interest (BRMN, CELG, REGN)",2013-09-25 12:52:00-04:00,FOLD,positive
509927.0,"Amicus, Biogen Announce Deal for Discovery, Development, Commercialization of Parkinson's Treatment",2013-09-10 07:32:00-04:00,FOLD,neutral
509928.0,"Amicus Therapeutics, Inc. Reports Q2 EPS of $(0.31) vs $(0.35) Est",2013-08-07 16:21:00-04:00,FOLD,neutral
509929.0,Amicus Therapeutics Announces Chaperone-Advanced Replacement Therapy in Development for MPS I,2013-06-25 07:36:00-04:00,FOLD,neutral
509930.0,"Market Wrap for Monday, June 17: Stocks Jump to Start Trading Week; Dow Rallies Triple Digits ",2013-06-17 16:21:00-04:00,FOLD,neutral
509931.0,Afternoon Market Losers,2013-06-17 12:29:00-04:00,FOLD,negative
509932.0,Morning Market Losers ,2013-06-17 10:17:00-04:00,FOLD,negative
509933.0,Amicus Therapeutics to Discuss Regulatory Strategy on 8:00 AM ET Conference Call,2013-06-17 06:50:00-04:00,FOLD,neutral
509934.0,"Amicus Therapeutics, Inc. Reports Q4 EPS of $(0.20) vs $(0.37) Est",2013-03-12 17:06:00-04:00,FOLD,neutral
509935.0,"Earnings Scheduled For March 12, 2013",2013-03-12 04:41:00-04:00,FOLD,neutral
509936.0,"Amicus Therapeutics Unveils Proprietary ""CHART"" Platform Technology",2013-03-04 07:45:00-05:00,FOLD,neutral
509937.0,Amicus Therapeutics Says Added 6-Month Results from Phase 3 Fabry Monotherapy Study Presented at LDN World Symposium Did Not Meet Primary Endpoint,2013-02-15 10:32:00-05:00,FOLD,neutral
509938.0,Amicus Therapeutics Spikes Lower,2013-02-15 10:32:00-05:00,FOLD,negative
509939.0,Amicus Therapeutics Advances Chaperone-ERT Combo Platform in Pompe Diesease,2013-02-14 07:36:00-05:00,FOLD,neutral
509940.0,"Amicus Offers FY13 Guidance, Update on Strategic Outlook",2013-01-07 07:43:00-05:00,FOLD,neutral
509941.0,Benzinga's Top Pre-Market Gainers,2013-01-04 08:09:00-05:00,FOLD,positive
509942.0,Amicus Announces Positive Phase 2 Results for Chaperone-Enzyme Replacement Therapy Co-Administration Study for Pompe Disease ,2013-01-04 07:32:00-05:00,FOLD,positive
509943.0,"Janney Capital Initiates Coverage on Amicus Therapeutics, Inc. at Buy, Announces $7.00 PT",2013-01-02 17:09:00-05:00,FOLD,neutral
509944.0,Stocks Hitting 52-Week Lows,2012-12-26 10:14:00-05:00,FOLD,negative
509945.0,Stocks Hitting 52-Week Lows,2012-12-21 10:15:00-05:00,FOLD,negative
509946.0,Benzinga's Top Pre-Market Losers,2012-12-21 08:31:00-05:00,FOLD,negative
509947.0,UPDATE: Wedbush Downgrades Amicus Therapeutics to Underperform on Phase III Challenges  ,2012-12-21 07:46:00-05:00,FOLD,positive
509948.0,"Wedbush Downgrades Amicus Therapeutics, Inc. to Underperform, Lowers PT to $1.50",2012-12-21 06:35:00-05:00,FOLD,negative
509949.0,"JP Morgan Maintains Overweight on Amicus Therapeutics, Inc., Lowers PT to $5.00",2012-12-20 10:46:00-05:00,FOLD,negative
509950.0,Benzinga's Top Pre-Market Losers,2012-12-20 08:20:00-05:00,FOLD,negative
509951.0,Amicus Therapeutics Shares Resume Trading Down 50%,2012-12-19 16:30:00-05:00,FOLD,positive
509952.0,PREVIEW: Amicus Therapeutics to Resume Trading at 4:30 PM ET,2012-12-19 16:09:00-05:00,FOLD,neutral
509953.0,"Amicus, Glaxo Release Top-Line Six-Month Primary Treatment Period Results from First Phase 3 Fabry Monotherapy Study",2012-12-19 16:06:00-05:00,FOLD,neutral
509954.0,Amicus Therapeutics Halted News Pending,2012-12-19 16:01:00-05:00,FOLD,neutral
509955.0,Amicus Therapeutics Files $145M Securities Shelf,2012-12-06 16:12:00-05:00,FOLD,positive
509956.0,Amicus Therapeutics Announces Additional Preliminary Results from Open Label Phase 2 Study,2012-11-08 21:34:00-05:00,FOLD,neutral
509957.0,"Capstone Initiated Coverage on Amicus Therapeutics at Buy, Announced PT to $7",2012-11-01 11:00:00-04:00,FOLD,neutral
509958.0,A Peek Into The Market Before The Trading Starts,2012-10-11 07:42:00-04:00,FOLD,neutral
509959.0,Amicus to Report Study 010 Results By End of the Year,2012-10-11 07:35:00-04:00,FOLD,neutral
509960.0,"Wedbush Securities Maintains Amicus Therapeutics at Neutral, Lowers PT from $8 to $6",2012-07-20 14:21:00-04:00,FOLD,positive
509961.0,"UPDATE: Canaccord Reiterates Buy Rating, Raises PT on Amicus Therapeutics",2012-07-18 10:14:00-04:00,FOLD,neutral
509962.0,"Canaccord Maintains Amicus Therapeutics at Buy, Raises PT from $10 to $11",2012-07-18 06:44:00-04:00,FOLD,neutral
509963.0,Amicus Therapeutics and GlaxoSmithKline Expand Fabry Disease Collaboration; GSK to Increase Ownership in Amicus to 19.9% with $18.6M Investment in Common Stock Priced at $6.30 Per Share ,2012-07-17 16:03:00-04:00,FOLD,positive
509964.0,Amicus Therapeutics Announces Publication of BLISS Quantitative Histology Method in Archives of Pathology & Laboratory Medicine ,2012-07-02 07:31:00-04:00,FOLD,positive
509965.0,ThinkEquity Initiates Coverage on Amicus Therapeutics at Buy,2012-06-29 06:48:00-04:00,FOLD,neutral
509966.0,Canaccord Maintains Buy Rating for Amicus Therapeutics ,2012-06-27 09:17:00-04:00,FOLD,neutral
509967.0,Amicus Therapeutics Announces Positive Preliminary Results From Ongoing Phase 2 Chaperone-Enzyme Replacement Therapy (ERT) Co-Administration Study for Pompe Disease ,2012-06-26 16:01:00-04:00,FOLD,positive
509968.0,"Benzinga's Top Upgrades with Color for May 8, 2012",2012-05-08 12:08:00-04:00,FOLD,positive
509969.0,UPDATE: J.P. Morgan Upgrades Amicus Therapeutics,2012-05-08 08:37:00-04:00,FOLD,neutral
509970.0,"JP Morgan Upgrades Amicus Therapeutics from Neutral to Buy, Announces PT of $8",2012-05-08 06:16:00-04:00,FOLD,positive
509971.0,"Amicus Therapeutics Names William D. Baird, III Chief Financial Officer ",2012-04-16 07:30:00-04:00,FOLD,neutral
509972.0,From Earlier: Amicus Therapeutics Prices Underwritten Offering of 10M Shares at $5.70 ,2012-03-02 08:30:00-05:00,FOLD,positive
509973.0,Amicus Therapeutics Announces Proposed Public Offering of Common Stock; No Amount Given ,2012-03-01 16:01:00-05:00,FOLD,negative
509974.0,Amicus Therapeutics To Present At 2012 RBC Conference Tomorrow,2012-02-28 11:13:00-05:00,FOLD,neutral
509975.0,Amicus Therapeutics Presents Patient Screening Profiles From Phase 3 Fabry Study  ,2012-02-13 07:31:00-05:00,FOLD,neutral
509976.0,Earnings Scheduled For February 13,2012-02-13 05:03:00-05:00,FOLD,neutral
509977.0,Amicus Therapeutics Presents Preclinical Studies of Chaperone AT3375 for Gaucher Disease ,2012-02-09 12:41:00-05:00,FOLD,neutral
509978.0,Amicus Therapeutics Awarded Grant From Muscular Dystrophy Association for Pompe Disease Program,2012-02-07 07:30:00-05:00,FOLD,positive
509979.0,Amicus Therapeutics Announces Positive Preliminary Results From Ongoing Phase 2 Chaperone-Enzyme Replacement Therapy Study,2012-01-06 07:31:00-05:00,FOLD,positive
509980.0,Amicus Therapeutics Completes Enrollment of 67 Patients in Phase 3 Study of Migalastat HCl for Fabry Disease ,2011-12-19 07:30:00-05:00,FOLD,neutral
509981.0,Amicus Therapeutics Announces Close of Patient Recruitment in First Phase 3 Study of Amigal for Fabry Disease  ,2011-10-19 07:31:00-04:00,FOLD,neutral
509982.0,Amicus Therapeutics and GlaxoSmithKline Commence Second Phase 3 Study of Amigal for Fabry Disease ,2011-09-12 07:31:00-04:00,FOLD,neutral
509983.0,Amicus Therapeutics Announces John F. Crowley to Return as Chairman and Chief Executive Officer,2011-06-29 07:31:00-04:00,FOLD,neutral
509984.0,"Hot Stocks to Buy on 4/25/11 and April 26, 2011- TZOO, NWD, JKS, SHZ, SINA, BIIB, CSNHD…",2011-04-25 10:57:00-04:00,FOLD,neutral
509985.0,J.P. Morgan Maintains Neutral on Amicus Therapeutics (FOLD),2011-04-19 09:57:00-04:00,FOLD,neutral
509986.0,Amicus Therapeutics Announces Transition of John F. Crowley from Chairman and CEO to Executive Chairman,2011-04-18 16:01:00-04:00,FOLD,neutral
509987.0,Amicus Therapeutics Reports Q4 EPS of $(0.48) vs. $(0.15),2011-02-14 16:14:00-05:00,FOLD,neutral
509988.0,Amicus Therapeutics Provides 2011 Guidance ,2011-01-11 08:08:00-05:00,FOLD,neutral
509989.0,Amicus Therapeutics Announces Third Quarter 2010 Financial Results,2010-11-08 16:16:00-05:00,FOLD,neutral
509990.0,Zacks #1 Rank Additions for Tuesday - Tale of the Tape,2010-11-02 09:35:00-04:00,FOLD,neutral
509991.0,"Mid-Day Market Movers (GLOI, THTI, CAGC, FOLD)",2010-08-12 13:18:00-04:00,FOLD,neutral
509992.0,FOLD Initiated With Buy At Canaccord,2010-04-06 09:10:00-04:00,FOLD,neutral
509993.0,FOLD Initiated With Market Perform,2010-03-31 08:47:00-04:00,FOLD,neutral
509994.0,List of 52-week Low Stocks,2009-10-15 13:28:00-04:00,FOLD,negative
509995.0,"Biggest Losers (CVM, SGEN, SCLN, FOLD, FTBK)",2009-10-05 12:24:00-04:00,FOLD,negative
509996.0,"Stocks to Watch (FOLD,BX,BANF,SCLN)",2009-10-05 06:07:00-04:00,FOLD,neutral
